Preclinical and clinical studies with recombinant human basic fibroblast growth factor

Area of Science:

• Biochemistry
• Regenerative Medicine
• Wound Healing Research

Background:

• Basic fibroblast growth factor (bFGF) is a key heparin-binding growth factor involved in diverse biological activities, notably wound repair.
• Recombinant human basic fibroblast growth factor (rh-bFGF) has been produced at clinical grade for therapeutic evaluation.
• Understanding the role of growth factors in tissue regeneration is crucial for developing advanced wound care strategies.

Purpose of the Study:

• To evaluate the efficacy of rh-bFGF in promoting epithelial wound healing in preclinical models.
• To assess the systemic absorption and toxicity profile of rh-bFGF following topical and intravenous administration.
• To provide a basis for initiating human clinical trials to investigate rh-bFGF's therapeutic potential.

Main Methods:

• In vivo studies utilizing experimental models of corneal and tympanic membrane wounds.
• Evaluation of epithelial healing rates in rh-bFGF treated versus control groups.
• Pharmacokinetic assessment of labeled rh-bFGF to determine systemic absorption.
• Acute and subchronic toxicity testing following various administration routes.

Main Results:

• rh-bFGF treatment demonstrated a statistically significant increase in epithelial healing rates in ocular and tympanic membrane wound models.
• Topical application of rh-bFGF in ocular models did not lead to systemic absorption of the intact molecule.
• Toxicology studies revealed no signs of local irritation or systemic toxicity with rh-bFGF administration.

Conclusions:

• rh-bFGF exhibits potent wound healing properties in preclinical settings.
• The safety profile of rh-bFGF supports its further investigation in human subjects.
• Ongoing clinical studies aim to confirm the tolerability and efficacy of rh-bFGF for skin and corneal wound healing.